Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
100
Participants
Timeline
Start Date
June 30, 2025
Primary Completion Date
July 31, 2028
Study Completion Date
December 31, 2030
Conditions
HER2-positive Breast CancerMetastatic Breast Cancer
Interventions
DRUG
Pyrotinib
400mg or 320mg qd
DRUG
Capecitabine
500mg tid
All Listed Sponsors
lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
NCT07019337 - Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter